The role of chromogranin A in the management of patients with phaeochromocytoma
- 6 July 2006
- journal article
- research article
- Published by Wiley in Clinical Endocrinology
- Vol. 65 (3) , 287-293
- https://doi.org/10.1111/j.1365-2265.2006.02591.x
Abstract
Chromogranin A (CgA) is the most accurate general marker of neuroendocrine tumours. Supranormal CgA concentrations have been recorded in patients with tumours of neuroectodermal origin such as phaeochromocytoma and paraganglioma.The present study was performed to assess the role of CgA determination in the management of patients with phaeochromocytoma, in comparison with urinary catecholamines and their metabolites.The patients studied included 22 cases with phaeochromocytoma at initial presentation or at relapse some years after surgical cure or during follow-up of a malignant phaeochromocytoma. Seventeen patients were evaluated before and after surgical removal of phaeochromocytoma. To assess the specificity of the hormonal parameters, 20 subjects were enrolled as controls; they were from a group of patients referred to our observation for possible phaeochromocytoma and who were subsequently proven not to have the disease.Urinary epinephrine and norepinephrine were supranormal in 82% and 77% of patients, respectively. Urinary metanephrines and normetanephrines were supranormal in 84% and 89% of patients, respectively. The combination of urinary metanephrine and normetanephrine had a sensitivity of 100% in identifying a phaeochromocytoma. CgA was supranormal in 91% of patients. Combining the results of CgA and urinary catecholamines (epinephrine and norepinephrine), the sensitivity for diagnosis of phaeochromocytoma was 100%. Urinary catecholamines, metabolites (metanephrine and normetanephrine) and CgA levels in patients with malignant phaeochromocytoma did not differ significantly from those of patients with benign lesions. In most cases, CgA normalized after surgery.Our results indicate that CgA is a good marker of phaeochromocytoma; measurement of CgA could have a role in the follow-up of patients operated on for phaeochromocytoma.Keywords
This publication has 22 references indexed in Scilit:
- Diagnosis and Localization of PheochromocytomaHypertension, 2004
- Pheochromocytoma: State-of-the-Art and Future ProspectsEndocrine Reviews, 2003
- The Chromogranin–Secretogranin FamilyNew England Journal of Medicine, 2003
- Malignant and Benign PheochromocytomaAnnals of the New York Academy of Sciences, 2002
- Chromogranin A, an “On/Off” Switch Controlling Dense-Core Secretory Granule BiogenesisCell, 2001
- Chromogranin A as Serum Marker for Neuroendocrine Neoplasia: Comparison with Neuron-Specific Enolase and the -Subunit of Glycoprotein HormonesJournal of Clinical Endocrinology & Metabolism, 1997
- Plasma Chromogranin A in Pheochromocytoma, Primary Hyperparathyroidism and Pituitary Adenoma in Comparison with Catecholamine, Parathyroid Hormone and Pituitary Hormones.Endocrine Journal, 1997
- Diagnostic specificity of serum chromogranin-A for pheochromocytoma in patients with renal dysfunctionJournal of Clinical Endocrinology & Metabolism, 1994
- Chromogranin A Storage and SecretionMedicine, 1991
- Secretion of Chromogranin A by Peptide-Producing Endocrine NeoplasmsNew England Journal of Medicine, 1986